SPRO - スマ―トプロス （Spero Therapeutics Inc.）

GSK plc (LON:GSK) has delivered strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations. Highlights Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines · Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding COVID-19 solutions · Specialty Medicines £11.3 billion +37% AER, +29% CER; HIV +20% AER, +12% CER; Oncology +23% AER, +17% CER; Immuno-inflammation and other specialty +29% AER +20% CER; COVID-19 solutions (Xevudy) sales £2.3 billion · Vaccines £7.9 billion +17% AER, +11% CER; Shingrix £3 billion +72% AER, +60% CER · General Medicines £10.1 billion +5% AER, +1% CER Prioritised investment and cost discipline support strong growth in operating profit and EPS · Total continuing operating margin 21.9%. Total EPS 371.4p > 100% primarily reflecting the gain from discontinued operations arising on the demerger of the Consumer Healthcare business.

Spero Therapeutics Inc. (NASDAQ:SPRO)’s traded shares stood at 0.43 million during the last session, with the company’s beta value hitting 0.78. At the close of trading, the stock’s price was $2.00, to imply an increase of 4.17% or $0.08 in intraday trading. The SPRO share’s 52-week high remains $13.35, putting it -567.5% down since that … After This Week’s 11.11% Gain In Spero Therapeutics Inc. (NASDAQ: SPRO), We Just Learned Something New Read More »

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5 th Annual Evercore ISI HealthCONx Conference, which is taking place virtually, November 29, 2022 through December 1, 2022. Details for the fireside chat are as follows:

In Wednesday’s session, Spero Therapeutics Inc. (NASDAQ:SPRO) marked $1.86 per share, down from $1.88 in the previous session. While Spero Therapeutics Inc. has underperformed by -1.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SPRO fell by -88.71%, with highs and lows ranging from $17.08 to […]

In the last trading session, 1.16 million shares of the Spero Therapeutics Inc. (NASDAQ:SPRO) were traded, and its beta was 0.77. Most recently the company’s share price was $2.03, and it changed around $0.03 or 1.50% from the last close, which brings the market valuation of the company to $69.43M. SPRO currently trades at a … Let’s Talk About How Spero Therapeutics Inc. (NASDAQ: SPRO) Stock Is Doing. Read More »

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5 th Annual Evercore ISI HealthCONx Conference, which is taking place virtually, November 29, 2022 through December 1, 2022. Details for the fireside chat are as follows:

In Wednesday’s session, Spero Therapeutics Inc. (NASDAQ:SPRO) marked $1.86 per share, down from $1.88 in the previous session. While Spero Therapeutics Inc. has underperformed by -1.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SPRO fell by -88.71%, with highs and lows ranging from $17.08 to […]

In the last trading session, 1.16 million shares of the Spero Therapeutics Inc. (NASDAQ:SPRO) were traded, and its beta was 0.77. Most recently the company’s share price was $2.03, and it changed around $0.03 or 1.50% from the last close, which brings the market valuation of the company to $69.43M. SPRO currently trades at a … Let’s Talk About How Spero Therapeutics Inc. (NASDAQ: SPRO) Stock Is Doing. Read More »

Spero Therapeutics, Inc. (NASDAQ:NASDAQ:SPRO) Q3 2022 Earnings Conference Call November 14, 2022 04:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations &…

Spero Therapeutics Earnings, Revenue Miss in Q3

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5 th Annual Evercore ISI HealthCONx Conference, which is taking place virtually, November 29, 2022 through December 1, 2022. Details for the fireside chat are as follows:

In Wednesday’s session, Spero Therapeutics Inc. (NASDAQ:SPRO) marked $1.86 per share, down from $1.88 in the previous session. While Spero Therapeutics Inc. has underperformed by -1.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SPRO fell by -88.71%, with highs and lows ranging from $17.08 to […]

In the last trading session, 1.16 million shares of the Spero Therapeutics Inc. (NASDAQ:SPRO) were traded, and its beta was 0.77. Most recently the company’s share price was $2.03, and it changed around $0.03 or 1.50% from the last close, which brings the market valuation of the company to $69.43M. SPRO currently trades at a … Let’s Talk About How Spero Therapeutics Inc. (NASDAQ: SPRO) Stock Is Doing. Read More »

Spero Therapeutics, Inc. (NASDAQ:NASDAQ:SPRO) Q3 2022 Earnings Conference Call November 14, 2022 04:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations &…

Spero Therapeutics Earnings, Revenue Miss in Q3